Adaptimmune Therapeutics PLC reports results for the quarter ended in June - Earnings Summary

Adaptimmune Therapeutics

09/08/2023 23:12

* Adaptimmune Therapeutics PLC  ADAP.OQ  reported a
quarterly
adjusted loss of 23 cents​​ per share for the quarter ended in
June. The mean expectation of eight analysts for the quarter was
for a loss of 11 cents per share.
    * Revenue fell 7.4% to $5.13 million from a year ago;
analysts
expected $8.92 million. 
    * Adaptimmune Therapeutics PLC's reported EPS for the
quarter was
a loss of 12 cents​.
    * The mean earnings estimate of analysts had risen by
about 6.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Adaptimmune Therapeutics PLC shares had fallen by 7.0%
this
quarter and lost 41.1% so far this year.
    * The company reported a quarterly loss of $21.39 million.
    * Wall Street's median 12-month price target for Adaptimmune
Therapeutics PLC is $3.80 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 9 at 10:12 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.11          -0.23          Missed
 Mar. 31 2023      -0.15          0.01           Beat
 Dec. 31 2022      -0.25          -0.18          Beat
 Sep. 30 2022      -0.24          -0.24          Met